What to know
Tuberculosis Cases and Percentages by Drug Resistance1: United States, 1993–2023
| Year | Total cases2 | Isoniazid (INH)-resistant3 | Fluoroquinolone resistant4 | Multidrug-resistant (MDR)5 | Pre-extensively drug-resistant (Pre-XDR)6 | Extensively drug-resistant (XDR)7 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | ||
| 2023 | 6,964 | 589 | (8.5) | 45 | (0.6) | 100 | (1.4) | 15 | (0.2) | 1 | (0.0) |
| 2022 | 6,426 | 550 | (8.6) | 54 | (0.8) | 99 | (1.5) | 18 | (0.3) | 5 | (0.1) |
| 2021 | 6,096 | 538 | (8.8) | 27 | (0.4) | 80 | (1.3) | 6 | (0.1) | 2 | (0.0) |
| 2020 | 5,585 | 461 | (8.3) | 25 | (0.4) | 56 | (1.0) | 7 | (0.1) | 1 | (0.0) |
| 2019 | 6,895 | 661 | (9.6) | 37 | (0.5) | 94 | (1.4) | 16 | (0.2) | 3 | (0.0) |
| 2018 | 6,884 | 642 | (9.3) | 40 | (0.6) | 104 | (1.5) | 15 | (0.2) | 1 | (0.0) |
| 2017 | 6,890 | 632 | (9.2) | 50 | (0.7) | 129 | (1.9) | 22 | (0.3) | 4 | (0.1) |
| 2016 | 7,041 | 651 | (9.2) | 43 | (0.6) | 97 | (1.4) | 17 | (0.2) | 1 | (0.0) |
| 2015 | 7,305 | 685 | (9.4) | 39 | (0.5) | 88 | (1.2) | 6 | (0.1) | 1 | (0.0) |
| 2014 | 7,105 | 687 | (9.7) | 38 | (0.5) | 94 | (1.3) | 13 | (0.2) | 2 | (0.0) |
| 2013 | 7,211 | 674 | (9.3) | 50 | (0.7) | 96 | (1.3) | 14 | (0.2) | 5 | (0.1) |
| 2012 | 7,451 | 685 | (9.2) | 38 | (0.5) | 88 | (1.2) | 11 | (0.1) | 2 | (0.0) |
| 2011 | 7,908 | 752 | (9.5) | 34 | (0.4) | 127 | (1.6) | 16 | (0.2) | 5 | (0.1) |
| 2010 | 8,225 | 692 | (8.4) | 28 | (0.3) | 106 | (1.3) | 10 | (0.1) | 2 | (0.0) |
| 2009 | 8,657 | 762 | (8.8) | 17 | (0.2) | 115 | (1.3) | 18 | (0.2) | 0 | (0.0) |
| 2008 | 9,808 | 835 | (8.5) | 41 | (0.4) | 107 | (1.1) | 14 | (0.1) | 6 | (0.1) |
| 2007 | 10,227 | 797 | (7.8) | 29 | (0.3) | 124 | (1.2) | 10 | (0.1) | 2 | (0.0) |
| 2006 | 10,476 | 845 | (8.1) | 26 | (0.2) | 124 | (1.2) | 12 | (0.1) | 4 | (0.0) |
| 2005 | 10,646 | 842 | (7.9) | 34 | (0.3) | 125 | (1.2) | 21 | (0.2) | 3 | (0.0) |
| 2004 | 11,096 | 872 | (7.9) | 28 | (0.3) | 128 | (1.2) | 21 | (0.2) | 4 | (0.0) |
| 2003 | 11,378 | 904 | (7.9) | 34 | (0.3) | 119 | (1.0) | 22 | (0.2) | 0 | (0.0) |
| 2002 | 11,549 | 914 | (7.9) | 32 | (0.3) | 158 | (1.4) | 23 | (0.2) | 6 | (0.1) |
| 2001 | 12,286 | 897 | (7.3) | 31 | (0.3) | 151 | (1.2) | 25 | (0.2) | 4 | (0.0) |
| 2000 | 12,557 | 981 | (7.8) | 28 | (0.2) | 146 | (1.2) | 20 | (0.2) | 1 | (0.0) |
| 1999 | 13,482 | 1,000 | (7.4) | 37 | (0.3) | 157 | (1.2) | 22 | (0.2) | 6 | (0.0) |
| 1998 | 14,272 | 1,120 | (7.8) | 36 | (0.3) | 155 | (1.1) | 26 | (0.2) | 1 | (0.0) |
| 1997 | 15,268 | 1,195 | (7.8) | 30 | (0.2) | 201 | (1.3) | 32 | (0.2) | 2 | (0.0) |
| 1996 | 16,329 | 1,284 | (7.9) | 23 | (0.1) | 250 | (1.5) | 42 | (0.3) | 3 | (0.0) |
| 1995 | 17,093 | 1,351 | (7.9) | 22 | (0.1) | 327 | (1.9) | 57 | (0.3) | 1 | (0.0) |
| 1994 | 17,622 | 1,543 | (8.8) | 41 | (0.2) | 431 | (2.4) | 78 | (0.4) | 6 | (0.0) |
| 1993 | 17,702 | 1,534 | (8.7) | 30 | (0.2) | 484 | (2.7) | 77 | (0.4) | 10 | (0.1) |
1Starting in 2023, information on drug resistance included results of molecular drug susceptibility testing in addition to growth-based susceptibility testing for isoniazid and rifampin. An isolate is considered resistant to isoniazid or rifampin if either the growth-based test or molecular test detects resistance.
2Persons with susceptibility results for at least isoniazid and rifampin.
3Resistance to at least isoniazid.
4Resistance to at least one fluoroquinolone (ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin, or other fluoroquinolones). For this report, fluoroquinolone resistance is based only on phenotypic results.
5Resistance to at least isoniazid and rifampin.
6MDR TB with additional resistance to either a fluoroquinolone or second-line injectable.
7MDR TB with additional resistance to fluoroquinolones and resistance to a second-line injectable, bedaquiline, or linezolid.
Note
Data for all years are updated through July 17, 2024.